AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18165596 — intervention group
Group type: EXPERIMENTAL
Intervention: IV patient-controlled tramadol
Number of subjects: 126
Study 16446021 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild memory impairment group (n = 30)
Number of subjects: 107
Study 16446021 — intervention group
Group type: COMPARATOR
Intervention: Normal elderly group (n = 77)
Number of subjects: 107
Study 12590006 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral alendronate (10 mg/day, n=18)
Number of subjects: 39
Study 12590006 — intervention group
Group type: COMPARATOR
Intervention: IV pamidronate (n=21)
Number of subjects: 39
Study 12590006 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 39
Study 11794823 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous combined hormone replacement therapy (0.625 mg conjugated estrogen/day combined with medroxyprogesterone 5 mg/day)
Number of subjects: 35
Study 11794823 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg/day
Number of subjects: 35
Study 11794823 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous combined hormone replacement therapy plus pravastatin
Number of subjects: 35
Study 9740079 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg once daily
Number of subjects: 764
Study 9740079 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole 10 mg once daily
Number of subjects: 764
Study 9740079 — intervention group
Group type: COMPARATOR
Intervention: Megestrol acetate 40 mg 4 times daily
Number of subjects: 764
Study 7992252 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ET and PV
Number of subjects: 33
Study 7992252 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ET and PV with previous thrombotic episodes
Number of subjects: 33
Study 7992252 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger patients with ET and PV
Number of subjects: 33
Study 7992252 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with PV
Number of subjects: 33
Study 7992252 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ET
Number of subjects: 33
Study 2659442 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 3 g amoxicillin (group A)
Number of subjects: 91
Study 2659442 — intervention group
Group type: COMPARATOR
Intervention: 4-day course of 3 X 750 mg amoxicillin (group B)
Number of subjects: 91
Study 4613531 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin F2alpha (PGF2alpha) administered extraamniotically
Number of subjects: 124
Study 4613531 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin F2alpha (PGF2alpha) administered intraamniotically
Number of subjects: 124
Study 4613531 — intervention group
Group type: EXPERIMENTAL
Intervention: Histopathological studies on gestational sacs (group 1: PGF2alpha extraamniotic, group 2: PGF2alpha intraamniotic, group 3: hysterotomy)
Number of subjects: 124
Study 30911991 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus coagulans Unique IS2 (2 billion CFU)
Number of subjects: 100
Study 30911991 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 100
Study 30594403 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial cellulose graft
Number of subjects: 120
Study 30594403 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat graft
Number of subjects: 120
Study 30594403 — intervention group
Group type: COMPARATOR
Intervention: Temporalis fascia graft
Number of subjects: 120
Study 30464914 — intervention group
Group type: EXPERIMENTAL
Intervention: i/v ceftazidine 1 gm bd with oral ciprofloxacin 750 mg bd
Number of subjects: 20
Study 30464914 — intervention group
Group type: COMPARATOR
Intervention: surgical debridement with oral ciprofloxacin 750 mg bd
Number of subjects: 20
Study 26466613 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg od (or 15 mg od in patients with moderate renal insufficiency)
Number of subjects: 0
Study 26466613 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (INR target 2.5)
Number of subjects: 0
Study 24433817 — intervention group
Group type: EXPERIMENTAL
Intervention: Manga comic
Number of subjects: 57
Study 24433817 — intervention group
Group type: COMPARATOR
Intervention: Non-health-related newsletter
Number of subjects: 57
Study 22229757 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE)
Number of subjects: 62
Study 22229757 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR)
Number of subjects: 62
Study 19106240 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-salt diet (LS; 50 mmol Na/d)
Number of subjects: 29
Study 19106240 — intervention group
Group type: COMPARATOR
Intervention: Usual-salt diet (US; 150 mmol Na/d)
Number of subjects: 29
Study 17145785 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed voriconazole tablets
Number of subjects: 20
Study 17145785 — intervention group
Group type: COMPARATOR
Intervention: Whole voriconazole tablets
Number of subjects: 20
Study 15000672 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group (n = 32) participated in a 12-week, 3 days per week, exercise and health education program
Number of subjects: 53
Study 15000672 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 21)
Number of subjects: 53
Study 11993619 — intervention group
Group type: EXPERIMENTAL
Intervention: High rate of fluid intake (H) - 120% of BW loss ingested as 60%, 40%, and 20% in the 1st, 2nd, and 3rd hours of recovery, respectively.
Number of subjects: 8
Study 11993619 — intervention group
Group type: COMPARATOR
Intervention: Low rate of fluid intake (L) - 120% of BW loss ingested at 24% x h(‐1) during 5 hours.
Number of subjects: 8
Study 11993619 — intervention group
Group type: EXPERIMENTAL
Intervention: High rate of fluid intake (H)
Number of subjects: 8
Study 10546017 — intervention group
Group type: COMPARATOR
Intervention: Sera from diabetic patients (type 1 and type 2) applied to N1E‐115 neuroblastoma cells
Number of subjects: 39
Study 10546017 — intervention group
Group type: COMPARATOR
Intervention: Sera from diabetic patients (type 1 and type 2) applied to VSC4.1 neuroblastoma cells
Number of subjects: 39
Study 10546017 — intervention group
Group type: COMPARATOR
Intervention: Sera from patients with motor neuropathy
Number of subjects: 39
Study 10546017 — intervention group
Group type: EXPERIMENTAL
Intervention: Sera from type 1 diabetic patients
Number of subjects: 39
Study 10546017 — intervention group
Group type: EXPERIMENTAL
Intervention: Sera from type 2 diabetic patients
Number of subjects: 39
Study 7795155 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/day beta‐carotene for 14 weeks
Number of subjects: 149
Study 7795155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 7795155 — intervention group
Group type: COMPARATOR
Intervention: Comparison with non-smokers (n = 54)
Number of subjects: 149
Study 1693411 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin combined with xylometazoline hydrochloride nose drops
Number of subjects: 141
Study 1693411 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxillary sinus drainage
Number of subjects: 141
Study 1693411 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study 1693411 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of maxillary sinus drainage and amoxicillin with xylometazoline
Number of subjects: 141
Study 388714 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline-7-acetic acid (T7AA)
Number of subjects: 13
Study 388714 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 30189465 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal masks
Number of subjects: 85
Study 30189465 — intervention group
Group type: COMPARATOR
Intervention: Oronasal masks
Number of subjects: 85
Study 30189465 — intervention group
Group type: COMPARATOR
Intervention: Nasal pillows
Number of subjects: 85
Study 30189465 — intervention group
Group type: COMPARATOR
Intervention: Oronasal masks (best adherence subgroup)
Number of subjects: 85
Study 28234636 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral catheter plus sciatic nerve blocks
Number of subjects: 165
Study 28234636 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine-based periarticular injection
Number of subjects: 165
Study 28234636 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine-based periarticular injection
Number of subjects: 165
Study 25275888 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg·kg(‐1))
Number of subjects: 14
Study 25275888 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 23841901 — intervention group
Group type: EXPERIMENTAL
Intervention: Alexander Technique lessons (20 sessions of 30 minutes each)
Number of subjects: 500
Study 23841901 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (12 sessions of 50 minutes each)
Number of subjects: 500
Study 23841901 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 500
Study 22001096 — intervention group
Group type: EXPERIMENTAL
Intervention: Mimic dVTrainer (MdVT)
Number of subjects: 16
Study 22001096 — intervention group
Group type: EXPERIMENTAL
Intervention: da Vinci Surgical System (dVSS)
Number of subjects: 16
Study 22001096 — intervention group
Group type: COMPARATOR
Intervention: No additional training (Control Group 3)
Number of subjects: 16
Study 19369530 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic mixture containing bifidobacteria and lactobacilli
Number of subjects: 0
Study 19369530 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17530106 — intervention group
Group type: EXPERIMENTAL
Intervention: Urea breath test (UBT)
Number of subjects: 120
Study 17530106 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaire on upper gastrointestinal (UGI) symptoms
Number of subjects: 120
Study 17530106 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between preclinical and clinical group of students
Number of subjects: 120
Study 15339328 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg/q.d.s.
Number of subjects: 349
Study 15339328 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 20 mg/q.d.s.
Number of subjects: 349
Study 15339328 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 10 mg/q.d.s.
Number of subjects: 349
Study 15339328 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg/b.d.
Number of subjects: 349
Study 11603627 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 MIU IFN‐β
Number of subjects: 0
Study 11603627 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 MIU IFN‐β
Number of subjects: 0
Study 9647334 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone
Number of subjects: 26
Study 9647334 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 9748034 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline
Number of subjects: 589
Study 9748034 — intervention group
Group type: COMPARATOR
Intervention: Non-selegiline (Control)
Number of subjects: 589
Study 9748034 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa plus Selegiline
Number of subjects: 589
Study 9748034 — intervention group
Group type: COMPARATOR
Intervention: Levodopa (Control)
Number of subjects: 589
Study 9748034 — intervention group
Group type: COMPARATOR
Intervention: Selegiline vs Non-selegiline
Number of subjects: 589
Study 9748034 — intervention group
Group type: COMPARATOR
Intervention: Selegiline/Levodopa vs Levodopa
Number of subjects: 589
Study 1825037 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary administration of acetylcholine or ergonovine
Number of subjects: 19
Study 1825037 — intervention group
Group type: EXPERIMENTAL
Intervention: Left coronary spasm
Number of subjects: 19
Study 1825037 — intervention group
Group type: EXPERIMENTAL
Intervention: Right coronary spasm
Number of subjects: 19
Study 1825037 — intervention group
Group type: COMPARATOR
Intervention: Nonprovoked cases
Number of subjects: 19
Study 6602993 — intervention group
Group type: EXPERIMENTAL
Intervention: Positional feedback stimulation training and cyclical electrical stimulation
Number of subjects: 40
Study 6602993 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy (Control)
Number of subjects: 40
Study 31775837 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus therapy with 20-40 ml/kg 5% albumin or 0.9% saline over 1-2 h
Number of subjects: 3138
Study 31775837 — intervention group
Group type: COMPARATOR
Intervention: No bolus (control, 4 ml/kg/hour maintenance)
Number of subjects: 3138
Study 31775837 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus therapy
Number of subjects: 3138
Study 29985860 — intervention group
Group type: EXPERIMENTAL
Intervention: Telenursing intervention with weekly follow-up phone calls for 12 weeks and availability of telenurse for calls anytime.
Number of subjects: 72
Study 29985860 — intervention group
Group type: COMPARATOR
Intervention: Control group with one follow-up phone call after 12 weeks.
Number of subjects: 72
Study 29985860 — intervention group
Group type: EXPERIMENTAL
Intervention: Telenursing program for caregivers.
Number of subjects: 72
Study 26818893 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin initiation willingness
Number of subjects: 261
Study 26818893 — intervention group
Group type: EXPERIMENTAL
Intervention: Socioeconomic status and insulin appraisals
Number of subjects: 261
Study 26818893 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression model
Number of subjects: 261
Study 24996223 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (Arm A)
Number of subjects: 60
Study 24996223 — intervention group
Group type: COMPARATOR
Intervention: Passive physical therapy (Arm B)
Number of subjects: 60
Study 23342560 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplemented milk containing Lactobacillus rhamnosus hct 70
Number of subjects: 40
Study 23342560 — intervention group
Group type: COMPARATOR
Intervention: Plain milk (Control)
Number of subjects: 40
Study 20518930 — intervention group
Group type: EXPERIMENTAL
Intervention: Gutta‐flow
Number of subjects: 38
Study 20518930 — intervention group
Group type: COMPARATOR
Intervention: AH‐Plus
Number of subjects: 38
Study 19190878 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) 1g/kg for two consecutive days (total dose 2 g/kg)
Number of subjects: 81
Study 19190878 — intervention group
Group type: COMPARATOR
Intervention: Intravenous anti-D immunoglobulin 75 microg/kg (single dose)
Number of subjects: 81
Study 16187243 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate (treatment)
Number of subjects: 11
Study 16187243 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 11
Study 14508352 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA-ME with C2 monitoring
Number of subjects: 296
Study 10378713 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 73
Study 10378713 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 73
Study 9133170 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative autotransfusion (MAT)
Number of subjects: 24
Study 9133170 — intervention group
Group type: COMPARATOR
Intervention: Homologous transfusion
Number of subjects: 24
Study 8229498 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime (8 mg/kg per day for 5 days)
Number of subjects: 77
Study 8229498 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMX, 10-50 mg/kg per day for 5 days)
Number of subjects: 77
Study 8229498 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime
Number of subjects: 77
Study 8229498 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMX)
Number of subjects: 77
Study 3492030 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation
Number of subjects: 5
Study 3492030 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulation
Number of subjects: 5
Study 3492030 — intervention group
Group type: COMPARATOR
Intervention: Placebo apparatus
Number of subjects: 5
Study 3492030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 31199595 — intervention group
Group type: EXPERIMENTAL
Intervention: Reconval K1 cream
Number of subjects: 0
Study 31199595 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline
Number of subjects: 0
Study 29526857 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal transcranial direct current stimulation over the contralesional cerebellar hemisphere + cathodal transcutaneous spinal direct current stimulation
Number of subjects: 20
Study 29526857 — intervention group
Group type: COMPARATOR
Intervention: Anodal transcranial direct current stimulation over the damaged cerebral hemisphere + cathodal transcutaneous spinal direct current stimulation
Number of subjects: 20
Study 26994228 — intervention group
Group type: EXPERIMENTAL
Intervention: GDHT (goal-directed haemodynamic treatment)
Number of subjects: 142
Study 26994228 — intervention group
Group type: COMPARATOR
Intervention: Routine fluid treatment (clinician-guided)
Number of subjects: 142
Study 24217219 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol infusion to increase plasma cortisol concentration to a level associated with major physiologic stress.
Number of subjects: 0
Study 24217219 — intervention group
Group type: COMPARATOR
Intervention: Saline pre-treatment (Control group).
Number of subjects: 0
Study 22440088 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 2
Study 22440088 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated blood pressure
Number of subjects: 2
Study 19567826 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch (21 mg/24 hr)
Number of subjects: 400
Study 19567826 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 400
Study 17167258 — intervention group
Group type: EXPERIMENTAL
Intervention: Probing with a sharp dental probe (No. 23) on occlusal surfaces with initial carious lesions.
Number of subjects: 18
Study 17167258 — intervention group
Group type: EXPERIMENTAL
Intervention: Probing with a sharp dental probe (No. 23) on sound occlusal surfaces.
Number of subjects: 18
Study 17167258 — intervention group
Group type: COMPARATOR
Intervention: Unprobed occlusal surfaces (negative controls).
Number of subjects: 18
Study 15637449 — intervention group
Group type: EXPERIMENTAL
Intervention: Female patients
Number of subjects: 17370
Study 15637449 — intervention group
Group type: COMPARATOR
Intervention: Male patients
Number of subjects: 17370
Study 12359986 — intervention group
Group type: COMPARATOR
Intervention: Dietary intervention program administered by a dietitian
Number of subjects: 140
Study 12359986 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention program administered by a doctor of chiropractic in conjunction with chiropractic spinal manipulation
Number of subjects: 140
Study 7954561 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 86
Study 7954561 — intervention group
Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 86
Study 7954561 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine and Captopril
Number of subjects: 86
Study 2900483 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 0
Study 2900483 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam
Number of subjects: 0
Study 2900483 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29255109 — intervention group
Group type: EXPERIMENTAL
Intervention: PsyScan e-tool intervention
Number of subjects: 336
Study 29255109 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 336
Study 28784536 — intervention group
Group type: EXPERIMENTAL
Intervention: Matcha tea
Number of subjects: 23
Study 28784536 — intervention group
Group type: EXPERIMENTAL
Intervention: Matcha tea bar (4 g matcha tea powder)
Number of subjects: 23
Study 28784536 — intervention group
Group type: COMPARATOR
Intervention: Placebo tea
Number of subjects: 23
Study 28784536 — intervention group
Group type: COMPARATOR
Intervention: Placebo bar
Number of subjects: 23
Study 26742400 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior TAP block
Number of subjects: 29
Study 26742400 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral TAP block
Number of subjects: 29
Study 26742400 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 29
Study 23565969 — intervention group
Group type: EXPERIMENTAL
Intervention: A + PAAC (Physical Activity Across the Curriculum)
Number of subjects: 687
Study 23565969 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 687
Study 21494061 — intervention group
Group type: EXPERIMENTAL
Intervention: Wisdom psychotherapy (PTED-specific cognitive behaviour therapy)
Number of subjects: 82
Study 21494061 — intervention group
Group type: EXPERIMENTAL
Intervention: Wisdom and hedonia psychotherapy
Number of subjects: 82
Study 21494061 — intervention group
Group type: COMPARATOR
Intervention: Routine multidimensional cognitive behaviour therapy
Number of subjects: 82
Study 19268068 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive patients with different left ventricular geometric patterns (concentric hypertrophy, eccentric hypertrophy, concentric remodeling, normal)
Number of subjects: 265
Study 19268068 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive patients with different left ventricular geometric patterns
Number of subjects: 265
Study 19268068 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 265
Study 19268068 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of diabetes at study entry
Number of subjects: 265
Study 16794200 — intervention group
Group type: EXPERIMENTAL
Intervention: Dispersible aspirin 75 mg
Number of subjects: 71
Study 16794200 — intervention group
Group type: COMPARATOR
Intervention: Enteric-coated 75 mg aspirin
Number of subjects: 71
Study 16794200 — intervention group
Group type: EXPERIMENTAL
Intervention: Asasantin (25-mg standard release aspirin plus 200-mg modified-release dipyridamole given twice daily)
Number of subjects: 71
Study 16794200 — intervention group
Group type: COMPARATOR
Intervention: Other aspirin preparations (3 different enteric-coated 75 mg aspirins)
Number of subjects: 71
Study 15185208 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion
Number of subjects: 4
Study 15185208 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 4